Health Care: Drugs

Proteostasis Therapeutics Inc (PTI: NASDAQ)

$11.27 0.14 | 1.26%
12/09/16 - 12:53 PM ET
Company Balance Sheet
Dec 2015 Dec 2014 Dec 2013
Assets
Cash and Equivalents 13.84M 8.79M 2.59M
Receivables 918.00K 1.42M 2.73M
Inventories 0.00 0.00 0.00
Other Current Assets 180.00K 370.00K 454.00K
Total Current Assets 14.94M 10.59M 5.78M
Property, Plant & Equipment, Gross 566.00K 3.32M 3.19M
Accumulated Depreciation & Depletion 0.00 2.75M 2.32M
Property, Plant & Equipment, Net 566.00K 575.00K 867.00K
Intangibles 0.00 0.00 0.00
Other Non-Current Assets 3.18M 620.00K 567.00K
Total Non-Current Assets 3.75M 1.20M 1.43M
Liabilities & Shareholder Equity
Total Assets 18.69M 11.78M 7.21M
Accounts Payable 3.33M 1.89M 700.00K
Short Term Debt 0.00 0.00 0.00
Other Current Liabilities 182.00K 62.00K 69.00K
Total Current Liabilities 9.84M 6.03M 2.93M
Long Term Debt 0.00 10.20M 0.00
Deferred Income Taxes 287.00K 470.00K 40.00K
Other Non-Current Liabilities 4.38M 3.31M 2.08M
Minority Interest 0.00 0.00 0.00
Total Non-Current Liabilities 116.96M 100.83M 78.01M
Total Liabilities 126.79M 106.87M 80.94M
Preferred Stock Equity 0.00 0.00 0.00
Common Stock Equity -108.10M -95.08M -73.73M
Common Par 1.00K 1.00K 0.00
Additional Paid In Capital 12.12M 93.00K 670.00K
Cumulative Translation Adjustment 0.00 0.00 0.00
Retained Earnings -120.22M -95.18M -74.40M
Treasury Stock 0.00 0.00 0.00
Other Equity Adjustments 0.00 0.00 0.00
Total Capitalization -108.10M -84.89M -73.73M
Total Equity -108.10M -95.08M -73.73M
Total Liabilities & Stock Equity 18.69M 11.78M 7.21M
Total Common Shares Outstanding 16.71M 16.71M 16.71M
Preferred Shares 0.00 0.00 0.00
Treasury Shares 0.00 0.00 0.00
Basic Weighted Shares Outstanding 0.00 0.00 0.00
Diluted Weighted Shares Outstanding 0.00 0.00 0.00
Number of Employees 41 NA NA
Number of Part-Time Employees 1 NA NA

Portfolios with PTI

Latest PTI Headlines from TheStreet

More Financial News for PTI

Press Releases for PTI

See All Press Releases
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter